EXECUTIVE ENGAGEMENTS
POOL
1802
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
324
Interactions with Platform & by Email
PARTICIPANTS
72
Unique # Participated
VALIDATIONS
16
Responses Validated*
COMPANIES
24
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
40
PAGES
94
EDITION
15
PRICE
USD 5450
CODE
MCP-6831
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Human Embryonic Stem Cell (hESC) Research estimated at US$650.9 Million in the year 2020, is projected to reach a revised size of US$1 Billion by 2027, growing at a CAGR of 6.5% over the analysis period 2020-2027. Regenerative Medicine, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$717.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Stem Cell Biology Research segment is readjusted to a revised 7.4% CAGR for the next 7-year period.
The Human Embryonic Stem Cell (hESC) Research market in the U.S. is estimated at US$192.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$177.3 Million by the year 2027 trailing a CAGR of 6.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.
In the global Tissue Engineering segment, USA, Canada, Japan, China and Europe will drive the 5.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$39.3 Million in the year 2020 will reach a projected size of US$55.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$116.4 Million by the year 2027.
SELECT PLAYERS
Astellas Institute of Regenerative Medicine; Asterias Biotherapeutics, Inc.; BD Biosciences; Cell Cure Neurosciences Ltd.; Cellular Dynamics International; GE Healthcare; PerkinElmer, Inc.; Reliance Life Sciences Ltd.; Research & Diagnostics Systems, Inc.; STEMCELL Technologies, Inc.; Stemina Biomarker Discovery, Inc.; Takara Bio, Inc.; TATAA Biocenter AB; Thermo Fischer Scientific Inc.; UK Stem Cell Bank; ViaCyte, Inc.
SEGMENTS
» Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Stem Cells Research: A Sunrise Sector in Biotechnology Arena |
| Human Embryonic Stem Cells - An Introduction |
| Embryonic Stem Cells - Sources and Cell Culture |
| Comparison on Adult and Embryonic Stem Cells |
| Advantages and Drawbacks of Various Stem Cells |
| Recent Market Activity |
| Human Embryonic Stem Cells - The Market Perspective |
| Timeline for Embryonic Stem Cell Research Activities: Major Events from 1963 through 2014 |
| Teratomas - No Longer an Impediment to Stem Cell Therapy Development |
| Human Embryonic and Induced Pluripotent Stem Cell Research Trends |
| Human Embryonic Stem Cell Research: Key Statistical Highlights |
| Research Topics on hESC and hiPSC by Number of Papers Published: 2011-2013 |
| Haploid Human Embryonic Stem Cell Line: The New Frontier |
| Human Induced Pluripotent Stem Cells Remains Best Alternative for hESC |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Astellas Institute of Regenerative Medicine (US) |
| Asterias Biotherapeutics, Inc. (US) |
| BD Biosciences (US) |
| Cell Cure Neurosciences Ltd. (Israel) |
| Cellular Dynamics International (US) |
| GE Healthcare (UK) |
| MilliporeSigma (US) |
| PerkinElmer, Inc. (US) |
| Reliance Life Sciences Ltd. (India) |
| Research & Diagnostics Systems, Inc. (US) |
| SABiosciences Corp. (US) |
| STEMCELL Technologies, Inc. (Canada) |
| Stemina Biomarker Discovery, Inc. (US) |
| Takara Bio, Inc. (Japan) |
| TATAA Biocenter AB (Sweden) |
| Thermo Fisher Scientific, Inc. (US) |
| UK Stem Cell Bank (UK) |
| ViaCyte, Inc. (US) |
| Vitrolife AB (Sweden) |
| 3. MARKET TRENDS & DRIVERS |
| Issues Hindering Development of hESC Research |
| Consideration of Best Translational Pathways Pivotal in Ensuring Growth Of hESCs |
| Ethical Issues and Technical Hurdles Bog Down hESC Research |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Stem Cell Biology Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Stem Cell Biology Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Human Embryonic Stem Cell (hESC) Research by Application - Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Human Embryonic Stem Cell (hESC) Research by Application - Percentage Breakdown of Value Sales for Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering and Toxicology Testing for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 24 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com